The split dosing approach maintains more consistent NNMT inhibition throughout the day, potentially enhancing metabolic benefits
This, in turn, boosts metabolic rate and activates a gene known as sirtuin-1 (SIRT1), also referred to as the "longevity gene." SIRT1 is involved in reducing the risk of various conditions such as diabetes, obesity, metabolic syndrome, atherosclerosis, cardiovascular disease, kidney disease, liver disease, neurodegeneration, and cancer.
Distinct from other common solid formulations constrained by gastrointestinal dissolution barriers, this liquid preparation boasts superior bioavailability and markedly enhanced intestinal absorption efficiency
Its given in doses of 500 mcg to 1 mg
Most current research-context subcutaneous protocols cite 300-500 mcg/day, but no published human pharmacokinetic study has formally evaluated the subcutaneous route
The one constant is consistency of timing and route for a mechanism that works by gradually shifting cellular metabolism, day-to-day steadiness matters more than any single dose